Hypoplastic Anaemia Treated by Transfusion of Foetal Haemopoietic Cells

Scott, Ronald Bodley; Matthias, J. Q.; Constandoulakis, M.; Kay, H. E. M.; Lucas, P. F.; Whiteside, J. D.

doi:10.1136/bmj.2.5264.1385

Cited by 18 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experience and that of Scott et al (1961) has proved disappointing and it must therefore be concluded that at present foetal liver suspensions are of little therapeutic value in the treatment of marrow failure. This finding is in agreement with the generally disappointing reports of the use of suspensions of adult marrow cells in similar cases.…”

Section: Discussionmentioning

confidence: 94%

“…However, four of these patients were in the terminal stages of their illness at the time of infusion and the other died three months later following the developmenit of frank monocytic blastic leukaemia. Scott et al (1961) have reported the results of giving foetal liver suspensioni to fourteen patients with idiopathic marrow failure and found it to be of temporary benefit in only two cases. These authors reported Ino untoward reactioii in aniy of the patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Foetal Liver Suspensions in the Treatment of Marrow Aplasia

Bridges¹,

Bridges²,

Edelstyn³

et al. 1965

Br J Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Foetal Liver Suspensions in the Treatment of Marrow Aplasia

Bridges¹,

Bridges²,

Edelstyn³

et al. 1965

Br J Cancer

View full text Add to dashboard Cite

“…Complicating GVHD was unlikely with donors younger than gestation week 12, although FLT from an 8-week-old embryo was followed by transient skin alterations [92]. Long-term survivors were tolerant to host-type antigens in the absence of demonstrable suppressor cells [44, 691. Since the initial report by Scott [93], more than 100 patients with aplastic anemia were transfused with FLC from 6 to 32-week-old fetuses [reviewed in 44, 45, [94][95][96]. Without adequate immunosuppressive host treatment, the low FLC dose administered in most cases resulted in transient engraftment in only a few instances [93,97].…”

Section: Fetal Liver Transplantation In Manmentioning

confidence: 99%

The fetal liver as an alternative stem cell source for hemolymphopoietic reconstitution

Prümmer

Fliedner

1986

The International Journal of Cell Cloning

View full text Add to dashboard Cite

In mammalian ontogeny, the liver constitutes the primary hematopoietic organ for some time. Fetal liver cells (FLC) are rich in hematopoietic stem cells with a high proliferative potential but contain few post-thymic T cells. In animal studies, FLC restored hematopoiesis without severe graft-versus-host disease. However, genetic disparity between donor and host frequently limited durable engraftment and prevented or protracted complete immune reconstitution in most fully allogeneic recipients. Some children with severe combined immunodeficiency have been cured by FLC infusion, whereas favorable effects in aplastic anemia, acute leukemia, and inborn errors of metabolism have been limited and badly understood. Fetal liver transplantation in animals may serve as a model for the analysis and management of complications associated with the transfer of purified hematopoietic stem cell grafts and aid in the development of future therapeutic strategies requiring rapidly proliferating stem cell populations.

show abstract

“…In 1961, a United Kingdom group reported the results of transplantation of fresh or stored fetal liver cells (1-20 ×10 9 /case, gestational age unknown) via intravenous injection to treat apoplastic anemia, stating that remission was achieved in two of 14 patients (18 mo to 55 years of age) [34] . Similar findings were subsequently reported from China [35,36] , Hungary [37] , India [38][39][40][41] , Italy [42][43][44] , and United States [45,46] .…”

Section: 'S To Mid-1980'smentioning

confidence: 99%

Fetal stem cell transplantation: Past, present, and future

Ishii

Eto

2014

WJSC

View full text Add to dashboard Cite

Since 1928, human fetal tissues and stem cells have been used worldwide to treat various conditions. Although the transplantation of the fetal midbrain substantia nigra and dopaminergic neurons in patients suffering from Parkinson's disease is particularly noteworthy, the history of other types of grafts, such as those of the fetal liver, thymus, and pancreas, should be addressed as there are many lessons to be learnt for future stem cell transplantation. This report describes previous practices and complications that led to current clinical trials of isolated fetal stem cells and embryonic stem (ES) cells. Moreover, strategies for transplantation are considered, with a particular focus on donor cells, cell processing, and the therapeutic cell niche, in addition to ethical issues associated with fetal origin. With the advent of autologous induced pluripotent stem cells and ES cells, clinical dependence on fetal transplantation is expected to gradually decline due to lasting ethical controversies, despite landmark achievements.

show abstract

Hypoplastic Anaemia Treated by Transfusion of Foetal Haemopoietic Cells

Cited by 18 publications

References 6 publications

Foetal Liver Suspensions in the Treatment of Marrow Aplasia

Foetal Liver Suspensions in the Treatment of Marrow Aplasia

The fetal liver as an alternative stem cell source for hemolymphopoietic reconstitution

Fetal stem cell transplantation: Past, present, and future

Contact Info

Product

Resources

About